Orphan Drugs Market 2015-2019

Price :
Published : Nov-2015
No. of Pages : 108

An orphan drug is used to treat rare diseases or disorders. According to WHO, orphan or rare diseases are the pathological conditions that affect 0.65-1 out of 10,000 population worldwide. There are around 6,000 orphan diseases, of which 80% are genetic. Orphan drugs are developed by the pharmaceutical industry to serve the public health need. These are designated as “Orphan Designations” by the regulatory agencies to accelerate the approval process.

The analysts forecast global orphan drugs market to grow at a CAGR of 10.05% over the period 2014-2019.

Covered in this report

The report covers the current scenario and the growth prospects of the global orphan drugs market for the period of 2015-2019. To calculate the market size, the report considers revenue generated from the sales orphan drugs.

The report, Global Orphan Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and Europe; it also covers the landscape of the global orphan drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • Europe

Key vendors

  • Bristol-Mayer Squibb
  • Celgene
  • F. Hoffmann La Roche
  • Novartis
  • Pfizer

Other prominent vendors

  • AbbVie
  • Actelion Pharmaceuticals
  • Alexion Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Amgen
  • AstraZeneca
  • Baxter International
  • Biogen Idec
  • Celldex Therapeutics
  • Eisai
  • Eli Lilly
  • GlaxoSmithKline
  • Intercept Pharmaceuticals
  • Johnson & Johnson
  • Merck
  • NewLink Genetics
  • Northwest Biotherapeutics
  • Novo Nordisk
  • Onyx Pharmaceuticals
  • Sanofi
  • Shire
  • Synageva BioPharma
  • Takeda
  • Vertex Pharmaceuticals
  • XOMA

Market driver

  • Shorter development timelines
  • For a full, detailed list, view our report

Market challenge

  • High cost of drug development
  • For a full, detailed list, view our report

Market trend

  • Increased focus on biological drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical
Publisher : Technavio
More Reports
Title Price Buy Now

Cevec Pharmaceuticals GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Cevec Pharmaceuticals GmbH (Cevec) is a healthcare products company that offers production of biopharmaceuticals. The company produces recombinant glycoproteins and gene therapy vectors. It utilizes its CAP-Go technology developed expression system based on human cells, for the production of complexly glycosylated molecules including coagulation factors and other plasma proteins. Cevec's CAP-GT cell lines provide a novel platform for the industrial production of adenoviral vectors, AAV and lentiviral vectors. The company provides CGMP manufacturing, cell line development, process development, and contract manufacturing services among others. It out-licenses its expression technology platform and product candidates through partnerships with biotechnology and pharmaceutical compan......

Harvard Stem Cell Institute – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Harvard Stem Cell Institute (HSCI), a subsidiary of Harvard University is a healthcare institute that conducts research on advance stem cell science using stem cell biology to develop new treatments and cures for disease. The institute provides research programs such as disease programs, core facilities, early-stage research, MD and PhD fellowship, and internship program. It undertakes various disease research programs, which include blood program, cardiovascular program, cancer program, diabetes program, kidney program, nervous system diseases program, and translation research program. The institute also offers clinical trial services. HSCI is headquartered in Cambridge, Massachusetts, the US. Harvard Stem Cell Institute - Pharmaceuticals & Healthcare - Deals and Alliances P......

Biowa Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Biowa Inc (BioWa), a subsidiary of Kyowa Hakko Kirin Co Ltd (KHK), is a science and technology company that provides out licensing of therapeutic antibody technologies of KHK. The company also developes fucose free monoclonal antibodies that increase cellular cytotoxicity. Its technology include potelligent, complegent and accretamab. BioWa's potelligent is used for ADCC enhancement of therapeutic antibodies; complegent is used for CDC enhancement of therapeutic antibodies. The company's accretamab is a combination of potelligent and complegent. Its ADCC/CDC enhanced monoclonal antibody based therapeutics used for other biotechnology and pharmaceutical companies for developing new therapies for the treatment of cancer and other diseases. The company partners include Bristol-Meye......

Geisinger Health System – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Geisinger Health System (GHS) is an integrated health services organization that provides medical and surgical specialties and sub-specialties, and related health services. It offers a range of medical services for patients suffering from diseases related to cardiology, ENT, gastroenterology, gynecology, cancer, obstetrics, ophthalmology, orthopedics and pediatrics, infectious diseases, and others. The organization also provides Life Flight regional helicopter ambulance services. It operates through several hospital campuses. GHS serves residents across several counties in central, south-central and northeast Pennsylvania; and southern New Jersey at AtlantiCare. The organization also offers medical education, research and community services. GHS is headquartered in Danville, Pen......

PhaseRx Inc (PZRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary PhaseRx Inc (PhaseRx), formerly PhaseRx Pharmaceuticals Inc is a healthcare products provider that conducts research and develops RNA nanomedicines for the treatment of orphan diseases. The company discovers and develops drugs based on SMARTT polymer technology, which offers mRNA delivery techniques. Its products under clinical development include PRX-OTC, PRX-ASL and argininosuccinatesynthetase. PhaseRx's SMARTT polymer technology provides platform for the development of RNA-based drugs. The company offers products for the treatment of inherited metabolic disease and liver cancer. It has research collaborations with pharmaceutical and biotechnology companies. PhaseRx is headquartered in Seattle, Washington, the US. PhaseRx Inc (PZRX) - Pharmaceuticals & Healthcare - Deals an......

U.S. HealthWorks Medical Group – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary U.S. HealthWorks Medical Group (U.S. HealthWorks), a subsidiary of Dignity Health is a healthcare service provider that offers physical therapy, rehabilitation and medical review. The center's services include occupational medicine, urgent care, specialty care and therapy services. Its occupational medicine services comprise physical abilities testing, injury treatment, national MRO services, employment physical exams, specialty care, client communication system, medical surveillance and therapy services. U.S. HealthWorks also provides urgent care treatments such as infections, high blood pressure, allergy relief, urinary tract infections, cold and flu, rashes, minor burns and injuries, cuts and wounds, cholesterol and asthma. The center's specialty care offers services on ortho......

International Drug Development Institute – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary International Drug Development Institute (IDDI) is a healthcare institute that offers clinical data collection, analysis, trial design and trial reporting services. The institute offers biostatistical services and eClinical services and risk-based monitoring programs. Its biostatistical and eClinical services comprise protocol design, central randomization, clinical data management, electronic data capture, biostatistics and medical writing. IDDI's risk-based monitoring services include risk indicator and central statistical monitoring. The institute provides clinical research services in therapeutics areas such as oncology, ophthalmology, cardiology and biosimilars. It caters to pharmaceutical companies, biotechs, start-ups, academic groups and CROs. IDDI is headquartered in Lo......

Camel-IDS NV – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Camel-IDS NV (Camel-IDS) is a biotechnology company which develops targeted radionuclide therapeutic solutions for the treatment of cancer. The company focuses on developing its lead compound radiopharmaceutical drug for treatment of Her2 positive cancer. Its technology platform is based on recombinant, small antigen-binding fragments derived from Camelidae heavy-chain-only antibodies (sdAbs) coupled with radioisotope to kill cancer cells. The company works in partnership with research institutions and organizations such as Vrije Universiteit Brussel (VUB), UZ Brussel, Fournier-Majoie Foundation, Biowin and VIB (Life Sciences Research Institute). Camel-IDS is headquartered in Brussels, Belgium. Camel-IDS NV - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides......

Edge Therapeutics Inc (EDGE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Edge Therapeutics Inc (Edge Therapeutics) is a clinical-stage biotechnology company that discovers, develops and commercializes a range of hospital-based therapies. The company offers hospital based therapies capable of transforming treatment paradigms in the management of life-threatening, acute neurological conditions. Its lead pipeline products include EG-1962, a proprietary formulation, which is used to treat aneurysmal subarachnoid hemorrhage, is in Phase 3 clinical trials and EG-1964 is in preclinical stage used to prevent recurrent chronic subdural hematoma. The company's Precise, a proprietary, programmable, biodegradable polymer-based development platform develops products for the treatment of acute neurological conditions. Edge Therapeutics is headquartered in Berkeley......

Veristat LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Veristat LLC (Veristat), a subsidiary of Veristat Holding Inc is a clinical research organization that conducts clinical trials. The organization offers clinical monitoring, clinical project management, data management, CDISC implementation, biostatistics, medical writing, project management, regulatory submissions-FDA representation, and statistical and strategic consulting services. It helps its clients design, execute, analyze, standardize, and report clinical studies. Veristat supports study phases in all therapeutic areas for every type of medical product. It caters to organization which develop biological products, diagnostics agents, vaccines, medical devices, immune therapies and gene therapies. Veristat is headquartered in Southborough, Massachusetts, the US. Verista......